Suparat Khamdang
Kyorin University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Suparat Khamdang.
Journal of The American Society of Nephrology | 2002
Atsushi Enomoto; Michio Takeda; Akihiro Tojo; Takashi Sekine; Seok Ho Cha; Suparat Khamdang; Fumio Takayama; Isao Aoyama; Sakurako Nakamura; Hitoshi Endou; Toshimitsu Niwa
In uremic patients, various uremic toxins are accumulated and exert various biologic effects on uremia. Indoxyl sulfate (IS) is one of uremic toxins that is derived from dietary protein, and serum levels of IS are markedly increased in both uremic rats and patients. It has been previously reported that the accumulation of IS promotes the progression of chronic renal failure (CRF). This study demonstrates the role of rat organic anion transporters (rOATs) in the transport of IS and the induction of its nephrotoxicity. The administration of IS to 5/6-nephrectomized rats caused a faster progression of CRF, and immunohistochemistry revealed that IS was detected in the proximal and distal tubules where rOAT1 (proximal tubules) and/or rOAT3 (proximal and distal tubules) were also shown to be localized. In in vitro study, the proximal tubular cells derived from mouse that stably express rOAT1 (S2 rOAT1) and rOAT3 (S2 rOAT3) were established. IS inhibited organic anion uptake by S2 rOAT1 and S2 rOAT3, and the Ki values were 34.2 and 74.4 microM, respectively. Compared with mock, S2 rOAT1 and S2 rOAT3 exhibited higher levels of IS uptake, which was inhibited by probenecid and cilastatin, organic anion transport inhibitors. The addition of IS induced a decrease in the viability of S2 rOAT1 and S2 rOAT3 as compared with the mock, which was rescued by probenecid. These results suggest that rOAT1 and rOAT3 play an important role in the transcellular transport of IS and the induction of its nephrotoxicity.
European Journal of Pharmacology | 2003
Suparat Khamdang; Michio Takeda; Ellappan Babu; Rie Noshiro; Maristela Lika Onozato; Akihiro Tojo; Atsushi Enomoto; Xiu-Lin Huang; Shinichi Narikawa; Naohiko Anzai; Pawinee Piyachaturawat; Hitoshi Endou
Cephalosporin antibiotics are thought to be excreted into the urine via organic anion transporters (OATs) and OAT can mediate nephrotoxicity by cephalosporins, particularly by cephaloridine. The purpose of this study was to elucidate the interaction of human-OAT2 and rat-OAT2 with cephalosporin antibiotics using proximal tubule cells stably expressing human-OAT2 and rat-OAT2. Human-OAT2 is localized to the basolateral side of the proximal tubule, whereas rat-OAT2 is localized to the apical side of the proximal tubule. Cephalosporins tested were cephalothin, cefoperazone, cefazolin, ceftriaxone, cephaloridine, cefotaxime, cefadroxil and cefamandole. These cephalosporins dose-dependently inhibited organic anion uptake mediated by human-OAT2 and rat-OAT2. There was no species difference observed for the effects of OAT2 with cephalosporins between human and rat transporters. Kinetic analysis revealed that the inhibitory effects for human-OAT2 were competitive. Cephaloridine significantly decreased the viability of cells stably expressing human-OAT2, human-OAT1, human-OAT3 and human-OAT4. The decreased viability of cells stably expressing human-OAT1, human-OAT3 and human-OAT4 but not human-OAT2 was reversed by probenecid. In conclusion, human-OAT2 interacts with cephalosporins, and thus, human-OAT2 may mediate the uptake of cephalosporins on the basolateral side of the proximal tubule. The interaction of human-OAT2 with cephalosporins was the weakest among the basolateral human-OATs tested. In addition, it is suggested that human-OATs mediate cephaloridine-induced nephrotoxicity.
Journal of Pharmacology and Experimental Therapeutics | 2002
Michio Takeda; Suparat Khamdang; Shinichi Narikawa; Hiroaki Kimura; Yasuna Kobayashi; Toshinori Yamamoto; Seok Ho Cha; Takashi Sekine; Hitoshi Endou
Journal of Pharmacology and Experimental Therapeutics | 2002
Michio Takeda; Suparat Khamdang; Shinichi Narikawa; Hiroaki Kimura; Makoto Hosoyamada; Seok Ho Cha; Takashi Sekine; Hitoshi Endou
Journal of Pharmacology and Experimental Therapeutics | 2002
Suparat Khamdang; Michio Takeda; Rie Noshiro; Shinichi Narikawa; Atsushi Enomoto; Naohiko Anzai; Pawinee Piyachaturawat; Hitoshi Endou
Journal of Biological Chemistry | 2004
Naohiko Anzai; Hiroki Miyazaki; Rie Noshiro; Suparat Khamdang; Arthit Chairoungdua; Ho-Jung Shin; Atsushi Enomoto; Shinichi Sakamoto; Taku Hirata; Kimio Tomita; Yoshikatsu Kanai; Hitoshi Endou
Journal of Pharmacology and Experimental Therapeutics | 2003
Habib Hasannejad; Michio Takeda; Kentarou Taki; Ho Jung Shin; Ellappan Babu; Promsuk Jutabha; Suparat Khamdang; Mahmoud Aleboyeh; Maristela Lika Onozato; Akihiro Tojo; Atsushi Enomoto; Naohiko Anzai; Shinichi Narikawa; Xiu-Lin Huang; Toshimitsu Niwa; Hitoshi Endou
Journal of Pharmacological Sciences | 2003
Mahmoud Alebouyeh; Michio Takeda; Maristela Lika Onozato; Akihiro Tojo; Rie Noshiro; Habib Hasannejad; Jun Inatomi; Shinichi Narikawa; Xiu-Lin Huang; Suparat Khamdang; Naohiko Anzai; Hitoshi Endou
Journal of Pharmacological Sciences | 2004
Suparat Khamdang; Michio Takeda; Minoru Shimoda; Rie Noshiro; Shinichi Narikawa; Xiu-Lin Huang; Atsushi Enomoto; Pawinee Piyachaturawat; Hitoshi Endou
Journal of Pharmacological Sciences | 2008
Kittipong Tachampa; Michio Takeda; Suparat Khamdang; Rie Noshiro-Kofuji; Minoru Tsuda; Surawat Jariyawat; Toshiyuki Fukutomi; Samaisukh Sophasan; Naohiko Anzai; Hitoshi Endou